Company Description
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States.
It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers.
The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products.
In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA.
Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
| Country | China |
| Founded | 2014 |
| IPO Date | Jun 12, 2020 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 674 |
| CEO | Yusheng Han |
Contact Details
Address: No. 5, Xingdao Ring Road North, International Bio Island Guangzhou, 510005 China | |
| Phone | 86 20 3403 7871 |
| Website | brbiotech.com |
Stock Details
| Ticker Symbol | BNR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| IPO Price | $16.50 |
| CIK Code | 0001792267 |
| CUSIP Number | 12233L107 |
| ISIN Number | US12233L2060 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Yusheng Han | Founder, Chairman and Chief Executive Officer |
| Xiaozhi Hu | Senior Director of Finance |
| Dr. Zhihong Zhang | Chief Technology Officer and Director |
| Hao Liu | Senior Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 6, 2025 | 6-K | Report of foreign issuer |
| Apr 29, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 25, 2025 | 6-K | Report of foreign issuer |
| Dec 31, 2024 | 6-K | Report of foreign issuer |
| Dec 4, 2024 | 6-K | Report of foreign issuer |
| Dec 3, 2024 | 6-K | Report of foreign issuer |
| Nov 27, 2024 | UPLOAD | Filing |
| Nov 26, 2024 | 20-F/A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | UPLOAD | Filing |